Thoughts on Gracell’s NMPA Accepted IND for GC019F a Rapidly Manufactured CD19 CAR-T
On Tuesday, January 19, Gracell Biotechnologies announced (press release) that the NMPA has accepted GC019F’s (FasTCAR-enabled autologous CD19 CAR-T) IND for treating patients with r/r adult B-ALL. Below, Celltelligence provides thoughts on Gracell’s recent IND approval and how the company’s focus on global GMP standards could allow Gracell to rapidly expand into the US and EU.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.